3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Genitourinary
1
Conditions
Vascular Calcification
1
Neoplasm Metastasis
1
Kidney Diseases
1
Hyperparathyroidism
1
Chronic Kidney Disease-Mineral and Bone Disorder
1
Bone Diseases
1
Interventions
Gemcitabine
43
pembrolizumab
36
Paclitaxel
36
Nivolumab
31
Docetaxel
29
Capecitabine
29
Bevacizumab
29
Oxaliplatin
28
Fluorouracil
28
Cisplatin
26
Leucovorin
24
Cyclophosphamide
23
Radiosurgery
20
Irinotecan
20
Carboplatin
20
aldesleukin
19
Cetuximab
19
Interleukin-2
16
fludarabine phosphate
15
fludarabine
15
Pemetrexed
15
Trastuzumab
14
Magnetic Resonance Spectroscopy
14
Ipilimumab
14
Fulvestrant
14
130-nm albumin-bound paclitaxel
14
Prednisone
13
Everolimus
13
Radiotherapy
12
Panitumumab
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neoplasm Metastasis
×
etelcalcetide hydrochloride
×
Clear all
NCT03960437
2023-09-21
Parsabiv-MBD
Columbia University
Phase 2
Completed
22 enrolled
14 charts